Publications by authors named "Nobumichi Tanaka"

Background: In Japan, since 2014, new treatments such as androgen receptor signaling inhibitors and cabazitaxel have become applicable for metastatic castration-resistant prostate cancer (mCRPC), leading to dramatic changes in treatment options.

Objective: This study aims to evaluate the impact of recent advancements in treatment options on the overall survival (OS) of patients diagnosed with de novo metastatic castration-sensitive prostate cancer (mCSPC) in Japan.

Methods: A retrospective analysis was conducted on 2450 Japanese men diagnosed with de novo mCSPC between 2008 and 2018.

View Article and Find Full Text PDF

: The standard recommendation for patients with non-muscle invasive bladder cancer is 5-aminolevulinic acid-mediated photodynamic diagnosis. The intensity of the fluorescence caused by the intracellular accumulation of protoporphyrin IX (PPIX) varies among tumors and patients. This study investigated the circadian rhythm of intracellular PPIX accumulation in bladder urothelial cancer cells exposed to 5-aminolevulinic acid.

View Article and Find Full Text PDF

Background: We investigated the roles of renal volumetry and histological features in the assessment of preoperative and postoperative renal function in living kidney donors (LKDs) including high-risk marginal donors (MDs).

Methods: We included 128 LKDs who underwent donor nephrectomy at our institution between 2006 and 2022. Clinical and radiographic data were retrospectively obtained from medical charts.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate how challenging laparoscopic adrenalectomy is by using the Mayo Adhesive Probability (MAP) score to assess issues with surrounding fat.
  • It involved a retrospective analysis of 103 patients, categorizing them based on preoperative CT scans into high and low MAP groups, comparing clinical features and analyzing tissue samples.
  • Results showed that high MAP patients were generally younger, had a higher proportion of males, and experienced significantly more blood loss during surgery, indicating a need for careful management in these cases.
View Article and Find Full Text PDF

Background/aim: Radiotherapy is one of the most frequently used options for prostate cancer (PCa). However, adverse effects related to irradiation of surrounding normal organs are significant clinical concerns. Specifically, genitourinary toxicity can dramatically reduce the quality of life.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated how prostate-specific antigen (PSA) levels and PSA bounce relate to cancer control after treatments like low-dose-rate brachytherapy (LDR-BT) and external beam radiotherapy (EBRT), with or without hormone therapy, while considering testosterone levels.
  • Researchers examined 944 prostate cancer patients to determine the impact of PSA levels (specifically 0.1, 0.2, or 0.5 ng/mL) and the occurrence of PSA bounce over several years post-treatment using statistical models.
  • Findings indicated that patients with normal testosterone who maintained lower PSA levels after treatment had significantly better outcomes in avoiding clinical failures, as did those who experienced a bounce in PSA levels during the early years.
View Article and Find Full Text PDF
Article Synopsis
  • This study evaluated health-related quality of life (HRQoL) in 42 patients with advanced urothelial carcinoma (aUC) receiving various immune checkpoint inhibitors (ICIs), including pembrolizumab, avelumab, and nivolumab.
  • Results showed significant improvements in HRQoL for patients on pembrolizumab, while those on avelumab and nivolumab experienced mostly stable or deteriorated HRQoL, particularly in social and general health aspects.
  • The findings suggest that despite the challenges, many patients on ICI therapy maintained a stable HRQoL, aligning with previous clinical trial evidence.
View Article and Find Full Text PDF

Background: A head-to-head comparison between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) revealed similar survival benefits for castration-resistant prostate cancer (CRPC) in the ENABLE study for PCa. Considering that a dose reduction of ENZ and ABI has demonstrated sufficient inhibitory ability of androgen receptor (AR) signaling, we analyzed the efficacy of modified doses of these agents in the ENABLE study for PCa.

Methods: This investigator-initiated, multicenter, randomized controlled trial that was conducted in Japan analyzed the prespecified survival endpoints, prostate-specific antigen (PSA) response rate ( ≥50% decline from baseline), and safety profile in patients treated with modified doses (ENZ ≤ 120 mg/day, ABI ≤ 750 mg/day) compared with those treated with a standard dose (ENZ 160 mg/day, ABI 1000 mg/day) as a starting dose.

View Article and Find Full Text PDF

Background: Controversial issues in registering candidates for deceased-donor kidney transplantation (DDKT) comprise various factors, including age, life expectancy, and dialysis duration. We investigated patient characteristics on the waiting list and discussed suitable criteria in Japan, which has a long waiting period.

Methods: This study included 592 patients on the waiting list for DDKT at our institute between 1982 and 2023.

View Article and Find Full Text PDF

Background: Urinary dysfunction is an adverse event of low-dose-rate brachytherapy (LDR-BT) in patients with prostate cancer. We aimed to examine the time to α-1 adrenergic antagonist withdrawal after LDR-BT initiation.

Methods: We retrospectively evaluated 1663 patients who underwent LDR-BT at our hospital during 2004-2022.

View Article and Find Full Text PDF

Background: Photodynamic diagnosis-assisted transurethral resection of bladder tumors (PDD-TURBT) enhances detection of elusive lesions compared to standard white light-transurethral resection of bladder tumors (WL-TURBT). If minimal light exposure during PDD-TURBT induces the accumulation of reactive oxygen species (ROS), potentially resulting in phototoxicity in small lesions, apoptosis may be triggered in residual small tumors, allowing them to escape resection. We investigated the hypothesis of a potential photodynamic therapeutic effect during PDD-TURBT.

View Article and Find Full Text PDF

Background: The clinical importance of nutrition and inflammation in patients with end-stage renal disease is well established. In this study, we investigated the role of nutritional and inflammatory indicators in the patient outcomes of living donor kidney transplant recipients.

Methods: We included 204 consecutive patients who underwent kidney transplantation at our institute between 2003 and 2022.

View Article and Find Full Text PDF

Background/aim: This study investigated the follow-up rate of living kidney donors and explored the factors related to continuous follow-up and remnant renal function, enabling the optimal management of living kidney donors.

Patients And Methods: We retrospectively evaluated 180 living kidney donors who underwent donor nephrectomies at our institute. Clinical information was obtained from medical charts, and remnant renal function was defined as the estimated glomerular filtration rate 12 months after donor nephrectomy.

View Article and Find Full Text PDF
Article Synopsis
  • Maintenance avelumab is recommended for patients with metastatic urothelial carcinoma (mUC) who have stable disease after first-line chemotherapy, while pembrolizumab offers an alternative option.
  • In a study of 626 patients, those transitioning from first-line chemotherapy to pembrolizumab had better outcomes in terms of response and progression-free survival compared to those moving to avelumab, especially if they had a partial response.
  • Overall survival rates were similar for both treatment options, highlighting that while pembrolizumab may provide better short-term efficacy, long-term survival outcomes remained unchanged.
View Article and Find Full Text PDF

Background: Although routine surveillance imaging to examine upper urinary tract urothelial cancer recurrence during follow-up of nonmuscle invasive bladder cancer is recommended, its necessity remains invalidated. A single-institute long-term follow-up cohort study to evaluate the clinical impact of routine surveillance imaging and identify risk factors for upper urinary tract urothelial cancer recurrence after nonmuscle invasive bladder cancer treatment was conducted.

Methods And Materials: A retrospective chart review of 864 patients with primary nonmuscle invasive bladder cancer who underwent initial transurethral resection of bladder tumor between 1980 and 2020 was conducted.

View Article and Find Full Text PDF

Background: It is unclear whether a hydrogel spacer can improve quality of life (QOL) in patients undergoing low-dose-rate brachytherapy (LDR-BT) alone or in combination with intensity-modulated radiotherapy (IMRT).

Methods: We enrolled patients with prostate cancer who underwent LDR-BT alone with (n = 186) or without (n = 348) a hydrogel spacer, or underwent LDR-BT in combination with IMRT with (n = 70) or without (n = 217) a hydrogel spacer. QOL was evaluated using Expanded Prostate Cancer Index Composite (EPIC) questionnaires at baseline and 1, 3, 6, 12, and 24 months after implantation.

View Article and Find Full Text PDF

A time-course questionnaire survey using the chemotherapy-induced taste alteration scale (CiTAS) was conducted in patients with advanced urothelial carcinoma (UC) treated with systemic chemotherapy and/or immunotherapy. A total of 37 patients receiving systemic therapy with enfortumab vedotin (EV), platinum-based chemotherapy and immune checkpoint inhibitors were included in this study. No significant changes were observed in any of the CiTAS subscales during platinum-based chemotherapy and immune checkpoint inhibitor treatment, while EV therapy induced significant dysgeusia.

View Article and Find Full Text PDF

The process and molecular mechanisms underlying the formation and destruction of a pseudo-capsule (PC) in clear cell renal cell carcinoma (ccRCC) are poorly understood. In the present study, the PCs of surgical specimens from primary tumors and metastatic lesions in 169 patients with ccRCC, and carcinogen-induced ccRCC rat models were semi-quantified using the invasion of PC (i-Cap) score system. This was based on the relationship among the tumor, PC and adjacent normal tissue (NT) as follows: i-Cap 0, tumor has no PC and does not invade NT; i-Cap 1, tumor has a complete PC and does not invade into the PC; i-Cap 2, tumor with focal absences in the PC, which partially invades the PC but not completely through the PC; i-Cap 3, tumor crosses the PC and invades the NT; i-Cap 4, tumor directly invades the NT without a PC.

View Article and Find Full Text PDF

Background: The severity of coronavirus disease 2019 (COVID-19) is known to be high in kidney transplant recipients; however, the risk factors for COVID-19 infection in these patients has not been studied extensively. Therefore, we explored the predictors of COVID-19 infection and severity in kidney transplant recipients in Japan.

Methods: This study included kidney transplant recipients who were regularly followed-up at our hospital from February 2021 to March 2023.

View Article and Find Full Text PDF

Background: Pseudoaneurysm formation sometimes complicates transplant nephrectomy. We report a case of bleeding from a pseudoaneurysm after transplantation nephrectomy that resulted in shock and emergency endovascular treatment.

Case Presentation: A 56-year-old man underwent transplant nephrectomy 3 years and 9 months following transplantation for pyelonephritis-related infection control.

View Article and Find Full Text PDF

Complete metastasectomy (CM) in metastatic renal cell carcinoma (mRCC) has demonstrated efficacy in the cytokine era, but its effectiveness in the era of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) remains unclear. A multi-institutional database included clinicopathological data of 367 patients with mRCC. Patients were divided into two groups: the CM group and the non-CM group.

View Article and Find Full Text PDF
Article Synopsis
  • - The study compares the effectiveness of enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) in treating nonmetastatic castration-resistant prostate cancer (CRPC) through a randomized controlled trial conducted in Japan.
  • - Results showed no significant differences in prostate-specific antigen (PSA) response rates and overall survival between ENZ (80%) and ABI (64%) groups, indicating both treatments have similar efficacy.
  • - The safety profiles were also comparable, with few patients experiencing serious adverse events, suggesting both ENZ and ABI are viable first-line treatment options for nonmetastatic CRPC.
View Article and Find Full Text PDF

Background: Living kidney donors are evaluated to determine their physical and psychological suitability for transplantation and ensure their safety. During this process, we frequently encounter cases where a donor is found to be ineligible. In this study, we surveyed donors who are ineligible for transplantation at our hospital to educate patients, their families, and medical staff regarding transplantation in the future.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to gather real-world evidence on the effectiveness and safety of enfortumab vedotin for treating unresectable or metastatic urothelial carcinoma in Japan, as data on this drug was limited.
  • Researchers analyzed data from 556 patients diagnosed with metastatic urothelial carcinoma between 2008 and 2023, including 34 patients who received enfortumab vedotin, assessing treatment responses and survival outcomes.
  • The results showed that 56% of patients had a partial response to the drug, with a median overall survival of 16 months and 76% experiencing some level of treatment-related toxicity, primarily skin issues.
View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the link between nutrition, inflammation, and patient outcomes in 253 individuals undergoing peritoneal dialysis (PD) from 2006 to 2021.
  • Results show that nutritional indicators and C-reactive protein (CRP) levels correlate with renal function and are significant predictors of survival and cardiovascular health for patients.
  • The research highlights the need for better management strategies for PD patients, as certain thresholds of nutritional and inflammatory indicators indicate higher mortality risks.
View Article and Find Full Text PDF